NCT06336291 - A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 22, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Glioblastoma

Interventions

DRUG

L19TNF

7 μg/kg

DRUG

L19TNF

10 μg/kg

DRUG

L19TNF

13 μg/kg

DRUG

Lomustine

90 mg/m2

DRUG

Lomustine

110 mg/m2

Trial Locations (8)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

19104

NOT_YET_RECRUITING

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

22903

NOT_YET_RECRUITING

University of Virginia (UVA), Charlottesville

60611

NOT_YET_RECRUITING

Northwestern Memorial Hospital, Chicago

02114

NOT_YET_RECRUITING

Massachusetts General Hospital (MGH), Boston

02215

NOT_YET_RECRUITING

Beth Israel Deaconess Medical Center (BIDMC), Boston

RECRUITING

Dana-Farber Cancer Institute (DFCI), Boston

All Listed Sponsors

lead

Philogen S.p.A.

INDUSTRY